Aspargo Labs Appoints Sam Backenroth As CFO To Drive Financial Strategy, Support U.S. And European Product Launches, And Accelerate Commercial Expansion

Aspargo Labs, Inc., a pharmaceutical company focused on commercializing a highly absorbent oral suspension spray technology designed to achieve rapid therapeutic exposure, has announced the appointment of Sam Backenroth as Chief Financial Officer. This appointment strengthens the company’s executive leadership as it enters the next phase of corporate growth and commercial expansion.

Mr. Backenroth brings nearly 20 years of senior financial and strategic leadership experience within the biotechnology sector. His background includes serving as CFO for multiple public and private companies across therapeutic areas such as ophthalmology, neurology, immunology, and oncology. Throughout his career, he has supported companies in accessing and navigating public markets, executing institutional capital raises, and creating significant enterprise value. His expertise spans capital markets transactions, public company reporting, investor engagement, and building scalable financial and governance infrastructure to support commercialization, operational growth, and long-term shareholder value.

Michael Demurjian, Chief Executive Officer of Aspargo Labs, emphasized that Mr. Backenroth has consistently demonstrated the ability to prepare companies for the rigor and expectations of the public markets. He noted that Sam’s experience in developing institutional-grade financial systems, combined with strategic flexibility and strong relationships within investment banking and the institutional investor community, will be instrumental as Aspargo executes its near-term priorities and long-term growth objectives.

Throughout his career, Mr. Backenroth has worked closely with boards and executive teams to align financial strategy with corporate goals, capital planning, and external engagement, particularly during key milestones and value inflection points. At Aspargo, he will partner with the executive team to drive ongoing U.S. and European product launches, support operational scaling, and advance new product development initiatives. His responsibilities will include aligning financial planning, capital strategy, and external communications with the company’s expanding commercial operations.

Expressing his enthusiasm for the new role, Mr. Backenroth stated that he is excited to join Aspargo at this pivotal stage in its growth. He highlighted the platform’s potential to deliver best-in-class products to patients at scale and expressed his commitment to translating that potential into sustainable growth while fostering innovation and long-term value for all stakeholders. The appointment of Sam Backenroth reflects Aspargo Labs’ continued focus on strengthening its leadership, governance, and financial foundation to support its future growth and commercial opportunities.